A classical function of C1q is to bind immune complexes and initiate complement activation producing membrane lytic complexes, opsonins and anaphylatoxins. This classical pathway of complement activation is also elicited when C1q binds some other ligands. Besides complement activation, C1q also regulates cell differentiation, adhesion, migration, activation and survival. C1q deficiency is associated with autoimmunity as well as increased susceptibility to infections. In this article, we discuss the basic properties of C1q, its expression, and classical and regulatory functions. Cellular & Molecular Immunology. 2008;5(1):9-21.
Introduction
Complement is a major arm of the host innate immune system providing critical protection against microbial infections. It can be activated through 3 different pathways, i.e., the classical, lectin and alternative pathways (1, 2) . The classical pathway is mainly elicited by immune complexesinvolving binding of C1q, which forms a pentameric complex with the C1r 2 C1s 2 serine protease tetramer, to the Fc regions of antibodies (1, 3) . Complement is also activated by other C1q ligands besides immune complexes. Ultimately, complement activation generates membrane-lytic complexes, opsonins and inflammatory anaphylatoxins (1) . Complement activation through the lectin pathway is initiated upon binding of the mannan-binding lectin (MBL) or ficolin, which complex with C1s-related serine proteases known as MBL-associated serine proteases (MASPs), to common carbohydrate structures on microorganisms (2, (4) (5) (6) . The alternative pathway is activated when low "tick-over" of C3 activation is amplified on microbial surfaces (1) . The alternative pathway can function independently and can also amplify the other two pathways.
C1q and MBL protects host against infections
In line with the role of C1q in complement activation, its deficiency causes increase in host susceptibility to microbial infections, e.g., Salmonella infections (7), malaria reinfection (8) , and polymicrobial peritonitis (9) . MBL deficiency is associated with increased susceptibility to childhood infections (10) . The latter is due to low complement activation on microbial surfaces and hence suboptimal opsonization with C3b and iC3b and insufficient phagocytosis (11) . MBL -/-mice show increased susceptibility to infections (12) .
C1q deficiency causes autoimmunity
While C1q deficiency is anticipated to render hosts more susceptible to microbial infections, the consistent association of C1q deficiency, in human and mice, with excessive inflammation and systemic lupus erythematosus (SLE)-like autoimmunity is not directly explained by its classical role in complement activation (13, 14) . Instead, it suggests immunosuppressive or tolerogenic roles for C1q. In this respect, the ability of the complement system to enhance apoptotic cell (AC) phagocytosis or clearance is relevant (15) . Excessive
C1q can directly opsonize AC for phagocytosis
C1q may enhance AC phagocytosis through several mechanisms. In vitro, C1q binds to surface blebs on AC but not normal host cells (17) . C1q binds to calreticulin (CRT) in AC blebs and opsonizes AC for enhanced phagocytosis through C1q interaction with CD91, which is also known as the 2-macroglobulin receptor or low-density lipoprotein receptor-related protein 1 (LRP-1), on phagocytes (18) . CRT is a ubiquitously expressed acidic Ca 2+ -binding protein in the endoplasmic reticulum (ER) (19) . Despite the finding of CRT expression within the ER it has also been reported as a receptor for C1q (cC1qR) and the collectins including MBL (20, 21) . CRT apparently moves to the surface on AC (18) . In this mechanism of C1q-mediated AC clearance, C1q directly opsonizes AC without eliciting complement activation.
C1q can indirectly opsonize AC through complement activation
C1q can also cause AC opsonization through complement activation (15) . AC can bind polyclonal IgM antibodies which then recruits C1q and activates the complement classical pathway (22) (23) (24) . IgM probably binds late but not early AC (22) . C3 deposition on AC enhances phagocytosis and, in this regard, complement receptor 3 (CR3) plays a critical role (15, 23, 25) . The other mechanism involves C1q binding to its ligand C-reactive protein (CRP) (26) . Like IgM, CRP also binds to phosphorylcholine on AC and then recruits C1q and elicits complement activation (27) . Binding of CRP to phosphorylcholine on bacteria also elicit C1q-mediated complement activation (28) . Compared with direct C1q opsonization, C1q-mediated C3 deposition on AC is likely to lead to more effective AC phagocytosis as a single C1q bound to AC can cause the deposition of many C3 molecules (1) . This is provided that the C3 activation does not cause excessive tissue damages and inflammation. In this connection, it must be noted that C3 activation was not required in C1q-mediated protection against glomerulonephritis (29).
Deficiencies in the classical pathway are associated with autoimmunity
Autoimmunity is associated with elevated immune complex formation and tissue deposition which activate complement as well as leukocytes (30) . Complement activation can cause tissue inflammation and damages and contribute to disease (31) . Then it is challenging to reconcile that deficiency in this pathway is prominently associated with increased autoimmunity (13, 32, 33) . Autoimmunity is mainly associated with deficiency of the early components of this pathway, especially C1q and C4, and association with deficiency of late complement components (i.e., C5-C9) has not been reported (33) . While C1q protection against autoimmunity may attribute to its ability to opsonize AC for phagocytosis, the counter argument is that MBL also binds AC and enhances AC phagocytosis through CD91 like C1q (18) , but its deficiency is not associated with autoimmunity (10) . MBL -/-mice show increased tissue AC but, unlike the C1q -/-mice, these MBL -/-mice showed no obvious autoimmunity (34) . This raises the question whether AC opsonization by C1q for enhanced phagocytosis represents a key host protective mechanism against autoimmunity.
The role of opsonic iC3b beyond AC phagocytosis
A possible difference between C1q and MBL, in response to AC, is the lack of report that MBL binding to AC also activates complement. MBL binding to AC surface CRT or cC1qR is expected to involve its collagenous domain and there is no evidence that this induces complement activation (18) . While C1q similarly binds to AC, it also binds IgM-and CRP-opsonized AC, through its globular domains, which can activate complement on AC causing deposition of iC3b (25, 27) .
Besides phagocytosis, the opsonic iC3b potentially promotes immune suppression or tolerance in phagocytes through stimulating CR3-simultaneous CR3 ligation inhibits LPS induction of IL-12 from macrophages (35, 36) . IL-12 is produced by antigen-presenting cells (APCs), like macrophages and DCs, and plays a major role in host T differentiation into IFN-γ producing Th1 cells (37) . TNF-α is a major inflammatory cytokine causing multiple inflammatory diseases (38) . Its production is also inhibited by CR3 signaling as a mechanism of immune evasion by fungal pathogen (39) . CR3-mediated AC phagocytosis indeed rendered DC tolerogenic (25) . In this connection, a defective complement classical pathway could lead to increased autoimmunity (13, 32, 33) .
C1q is synthesized by macrophages
Most complement proteins are synthesized in the liver by hepatocytes (40) . However, macrophages can synthesize early complement components of both the classical and alternative pathways and can provide sufficient local tissue complement for opsonization without recruiting plasma complement (40) . C1q is unusual, for a complement protein, that it is synthesized by tissue macrophages but not hepatocytes (41) (42) (43) . While there are also earlier indications that C1q is synthesized by other cell types, Petry et al. (2001) showed clearly the hemapoietic origin of C1q in vivo (44) . They showed that, when wild type mouse bone marrow was transferred to irradiated C1q -/-mice, C1q production was restored in the recipient mice and, when irradiated wild type mice received bone marrow from C1q -/-mice, C1q production was not detected (44) . Tissue macrophages originate from the monocyte precursors in blood circulation (45 
C1q is synthesized by monocyte-derived DCs
Besides macrophages, monocytes can also differentiate into DCs and, like macrophages, DCs also populate peripheral tissues (48, 49) . How DCs synthesize complement proteins is unclear. A recent report shows that C3 -/-DCs preferentially stimulate CD4 T cells into Th2 and regulatory T cells (50) . The first report that DCs synthesize C1q came from immunohistochemical staining of spleen, in which C1q was detected in interdigitating cells (51) . DCs are major APCs that exhibit two distinct maturation stages (49) . Peripheral tissue DCs are mostly immature DCs (imDCs) which are potent phagocytes and, upon activation, DCs down-regulate these properties and migrate to draining lymph nodes as mature DCs (mDCs). imDCs synthesize C1q but there are conflicting reports as to whether, or not, mDCs synthesize C1q (47, 52) . The detection of C1q in interdigitating cells in the spleen also suggests C1q synthesis by mDCs (51) . Macrophages are abundant in tissues and are probably the major source of blood C1q. It is unclear how DCs contribute to blood C1q. Nonetheless, there is growing evidence that C1q can regulate DC differentiation and activation affecting DC stimulation of T cells.
Regulation of C1q production
While macrophages and DCs constitutively produce C1q, it is also regulated by factors of microbial and host origins (Table 1) . Toll-like receptor (TLR) ligands such as lipopolysaccharide (LPS), peptidoglycan (PGN), lipoteichoic acid (LTA) and zymosan up-regulate C1q production by macrophages or DCs but LPS has also been reported to inhibit C1q production. Inflammatory cytokines also regulate C1q expression. Limited data show that IL-6 increases but IL-1 inhibits C1q production from macrophages. IFN-γ has been found to increase or inhibit C1q expression from different studies. Simian immunodeficiency virus (SIV) infection increased C1q production by macrophages. Immune complexes also up-regulate C1q expression. The up-regulation of C1q by microbial and inflammatory stimuli appears consistent with the classical role of C1q in complement activation against microbial infections. The down-regulation of C1q expression by IFN-γ, IL-1 and LPS is less understood. It should be noted that C1q up-regulation by some of these factors could be transient which is followed by down-regulation (58) . Drugs like phorbol 12-myristate 13-acetate (PMA) and tacrine inhibit C1q production. PMA inhibits C1q production by THP-1 cells and tacrine inhibits C1q up-regulation by IFN-γ (55) . Some non-steroidal drugs inhibit C1q production from thioglycollate-treated macro- phages but the same drugs up-regulated C1q production from resident macrophages (62) . It is unclear whether these drugs affect the development of autoimmune conditions. It is interesting to note that C1q expression is generally up-regulated under immunosuppressive conditions. For example, a microarray study revealed that tumor-associated macrophages expressed elevated levels of C1q and two major immunosuppressive cytokines IL-10 and TGF-β (57). Immunosuppresive drugs like dexamethasone, prednisone and hydrocortisone all promoted C1q production from macrophages (Table 1) .
Biochemical aspects of C1q
The biochemical characterization of C1q was mostly completed in 1970s and, as a result, a model was proposed for C1q (65) . A C1q molecule consists of 18 polypeptide chains of three different types (6 A-chains, 6 B-chains, and 6 C-chains) (Figure 1) . Each polypeptide consists of a collagenous N-terminal half and a globular C-terminal half with the collagenous region from each of the three chain types forming a triple helix bringing the 3 C-terminal globules together. A C1q consists of 6 such triple helical structures which are held together through inter-chain disulphide bonds at the N-terminal ends (Figure 1 ). It is viewed as a "bundle-of-tulips" under the electron microscope (66) . Earlier work has established conditions for the selective degradation of the collagenous or globular regions of C1q to evaluate the functions of each region in the absence of the other (67, 68) . The overall theoretical isoelectric point (pI) of the three C1q chains is 9.03 showing that it is a highly basic protein (http://au.expasy.org/tools/pi_tool.html).
Collagens are characterized by Gly-Xaa-Yaa repeating sequences where Xaa and Yaa are often proline residues and Yaa is often hydroxylproline or hydroxyllysine residues (69). This is also true for the collagenous halves of the C1q polypeptides (67) . Post-translational hydroxylation of proline and lysine residues is critical to the expression of C1q and other collagen-containing proteins. Two inhibitors of this process, i.e., 2,2'-dipyrodyl (DP) and 3,4-dehydro-DL-proline (DHP), have been used to block C1q synthesis in macrophages to generate C1q-deficient macrophages before C1q -/-macrophages became available from knockout mice (41, 70) . However, macrophages generated with these inhibitors are also expected to lack collagen expression.
C1q binds pentraxins
Many molecules or structures bind to C1q but the consequences of the binding vary substantially ( Table 2 ). The C1r 2 C1s 2 tetramer associates with the collagenous region of C1q and the C1r and C1s proenzymes are activated upon C1q binding to the Fc regions of antibodies through its globular domains (1) . This triggers the complement classical pathway. Another well-studied C1q-binding molecule is CRP. C1q binds to CRP and similarly activates the complement classical pathway (27, 28) . The difference between CRP and immune complexes as C1q ligands is that CRP but not immune complexes also binds factor H (71). CRP also up-regulates complement inhibitory proteins such as CD59, decay-accelerating protein (DAF) and membrane co-factor protein (MCP) on target cells (72) . These mechanisms act to limit complement activation within the early components of the cascade which causes effective opsonization with C3 and C4 fragments for phagocytosis while minimizing the formation of anaphylatoxins and membrane-lytic complement complexes and therefore minimizing tissue inflammation and damage (71) (72) (73) . CRP and another pentraxin serum amyloid P component (SAP) both bind to chromatin on AC and recruit C1q to elicit complement activation (27, 73) . C1q also binds to another pentraxin (PTX3) which inhibits C1q deposition on AC (53) . PTX3 was also reported to binds AC, but it binds to domains on AC that are distinct from the C1q-binding domains. Therefore, PTX3 apparently inhibits C1q binding to AC by blocking the AC-binding site on C1q (53) . Both PTX3 and C1q are produced by activated DCs. These pentraxins can apparently co-operate to regulate C1q-mediated complement activation on AC. Besides their structural similarities, these three pentraxins also have the common property of being acidic with low pI values ( Table 2 ). This is in contrast to the high pI value of C1q. In fact, most other C1q-binding molecules are also acidic ( Table 2) .
Cell-associated C1q ligands or receptors
A number of C1q-binding proteins are cellular proteins. CRT was first identified as a receptor for C1q that binds to the collagenous region of C1q (20, 21) . It is a ubiquitous Ca 2+ -binding protein which is naturally retained in the ER lumen and lacks a transmembrane domain (19) . On AC, it is found in blebs (18) . Its role as a C1q receptor (cC1qR) to modulate C1q-opsonized phagocytosis or signaling is doubtable, but its ability to tag AC for C1q recognition and phagocytosis through CD91 renders the C1q-CRT interaction a valid mechanism (18) . CRT is an acidic protein with a pI value of 4.29. CD91 is a type I receptor which also has an acidic extracellular domain (pI, 5.16).
gC1qR is another acidic cellular protein (pI, 4.74) that binds to C1q; it binds to the globular, rather than collagenous domains of C1q (74) . It is naturally expressed in the mitochondria lacking a transmembrane domain and its expression on the cell surface is not consistently reported (75, 76) . Nonetheless, treatment of macrophages and DCs with anti-gC1qR antibodies, aiming at gC1qR ligation, was shown to activate phosphatidylinositol 3-kinase (PI3K) and inhibit LPS induction of IL-12 from these cells (77) . While it is difficult to reconcile between mitochondrial expression of gC1qR and its response to extracellular molecules, the report of gC1qR expression on DCs upon maturation bridges these differences (78).
CD93 and CD35
Besides CD91, another two cell surface transmembrane proteins bind to C1q. CD93 was identified for its ability to recognize immobilized C1q and promote macrophage phagocytosis through Fc and complement receptors (79-81). Listed are proteins that have been reported to bind C1q. Some are soluble secreted proteins (CRP, SAP and PTX3), some are typical transmembrane receptors (CD35, SIGN-R1, CD91, CD93 and integrin α2β1), and some are cellular proteins without transmembrane domains which have been reported on the cell surface (cC1qR and gC1qR). cC1qR is also known as an endoplasmic reticulum protein calreticulin (CRT). gC1qR is also known as the mitochondria protein p33. CD91 is also known as α2-macroglobulin receptor or low-density lipoprotein receptor-related protein 1 (LRP-1). CD35 is complement receptor 1 (CR1). CD93 is also known as C1qRp. SAP, serum amloid P component; CRP, C-reactive protein; AC, apoptotic cell. NA, not determined. The isoelectric points (pIs) of each C1q-binding protein are indicated which were theoretical and were derived from the amino acid sequences of each mature peptide (http://au.expasy.org/tools/pi_tool.html). Sources of data are indicated by the numbered reference articles (Ref).
It recognizes the collagenous region of C1q and is also known as C1qRp (79, 80) . It is a type I receptor that contains a C-type carbohydrate recognition domain (CRD) and 5 EGF-like domains in its extracellular domain (80, 81) . Like most other C1q-binding proteins, the extracellular domain of CD93 is also acidic (pI, 4.95). With regard to AC phagocytosis, CD93 appears to function independently of C1q -C1q opsonization which is not required in CD93-mediated phagocytosis of AC (82) . CD35 or complement receptor 1 (CR1) is the least acidic C1q-binding protein known so far (PI, 6.57) (83).
C1q regulates multiple macrophage activities
Through interactions with soluble and cellular molecules, C1q modulates a range of macrophage interaction with microbial pathogens (Figure 2 ). C1q binds to Listeria monocytogenes and directly opsonizes the bacteria for enhanced macrophage uptake (84) . C1q opsonization of L. monocytogenes enhances IFN-γ induced superoxide (O 2 -) and nitric oxide (NO) production from macrophages leading to increased cytotoxicity (85) . Without obvious requirement for ligands, soluble C1q can stimulate macrophage production of TNF-α and up-regulate C3 (86) . In a recent study, another mechanism was described by which C1q mediates complement activation on Streptococcus (S.) pneumoniae without binding to the bacteria (87) . Both C1q and S. pneumoniae bind to the lectin receptor SIGN-R1 on a subpopulation of spleen macrophages (87) . C1q binding to SIGN-R1 elicits complement activation which apparently "spills" over to the surface of the bacteria leading to bacterial killing and clearance (87) . A mechanism by which soluble C1q enhances macrophage cytotoxicity is its increased expression by IFN-γ and its autocrine up-regulation of TNF receptor expression on macrophages (88, 89) . As a result, the elevated TNF receptor enhances autocrine macrophage stimulation by TNF-α which is induced by lipid A and these collectively lead potent NO production (88, 89) . In one report, C1q was shown to inhibit alveolar macrophage phagocytosis of serum-opsonized yeast (90) .
C1q can directly and indirectly opsonize AC for phagocytosis by macrophages. C1q can directly bind AC and mediate AC phagocytosis through CD91 or LRP-1 on macrophages (18) . It can also bind indirectly, through CRP and IgM, to cause complement activation and C3 deposition (24, 27, 73) . SAP binds to chromatins in AC blebs and C1q binds to SAP to activate complement (91) . Interestingly, like C1q -/-mice, SAP -/-mice also exhibit autoimmunity (91) . Phagocytosis of C1q-opsonized AC through CD91, also known as LRP-1, induced ERK activation in a manner which requires the expression of ATP-binding cassette member A7 (ABCA7) (92) . ERK activation promotes IL-10 but suppresses IL-12 production (93). However, the extent to which this mechanism contributes to AC induction of tolerogenic APCs has not been evaluated. Table 3 . The effects of soluble C1q (sC1q) and immobilized C1q (imC1q) on the various cell types are separately grouped. The C1q effector mechanisms are further grouped based on specific cell types. Mac, macrophage; Mo, monocyte; Neu, neutrophil; Fib, fibroblast; O 2 -, superoxide; NO, nitric oxide; MHC, major histocompatibility complex. The reference articles from which data were obtained are listed.
As C1q deposits around tissue macrophages (47) , understanding macrophage response to tissue-deposited or in vitro immobilized C1q is physiologically relevant. In this regard, immobilized C1q has been reported to engage CD93 on macrophages to enhance phagocytosis through Fc and complement receptors (79) (80) (81) . It should be noted that, while CD93 is involved in AC phagocytosis and clearance, there is no evidence that C1q was involved in this process (82) .
C1q regulates DC differentiation, activation and antigen presentation
C1q regulates several aspects of DC functions (Figure 2 ). It has been consistently reported to opsonize AC for DC phagocytosis (23, 53, 94, 95) . C1q-opsonized AC also regulates DC production of cytokines, but data from different studies are not entirely consistent. In one study, C1q was shown to increase IL-12 production by DCs when the cells were co-stimulated with LPS and AC (53) . In another study, C1q-opsonized AC was shown to induce IL-6, IL-10 and TNF-α from DCs but not IL-12 (94) . C1q
-/-mice have higher serum IL-12p40 than wild type mice suggesting inhibition of IL-12p40 production by normal C1q production (95) . When DCs were derived from the bone marrow of C1q -/-mice, these cells showed reduced NF-κB, p38, c-Jun and ERK activation and decreased IL-12p40 and TNF-α upon LPS stimulation (95) . However, these C1q -/-DCs showed normal CD40 and CD86 expression. As stated above, ligation of gC1qR on DCs inhibited LPS-induction of IL-12 through PI3K activation (77) . Apparently, most studies report C1q inhibition of IL-12 production from DCs and suggest a tolerogenic property of C1q which is consistent to the development of autoimmunity at C1q deficiency (14) .
C1q deposits in extracellular matrix around DCs (47). DCs have also been cultured on immobilized C1q (96, 97) . Immobilized C1q was shown to activate DCs --it up-regulated co-stimulatory molecules and induced cytokines including IL-10, IL-12 and TNF-α (96, 97) . These C1q-activated DCs also stimulated T cell proliferation and the production of IFN-γ (96, 97) . In contrast, DCs cultured from monocytes in the presence of soluble C1q exhibited tolerogenic or immunosuppressive properties (98) . These C1q-DCs expressed reduced co-stimulatory molecules and less cytokines and are also poorer in stimulating T cell proliferation and IFN-γ production (98) . C1q has been reported to stimulate immature DC chemotaxis through gC1qR and gC1qR (99) .
C1q regulates monocytes
Monocytes are blood precursors of tissue macrophages and DCs which are constitutively under the stimulation of plasma C1q. Nonetheless, C1q has been reported to stimulate monocyte chemotaxis (100) . However, C1q does not stimulate alveolar macrophage chemotaxis (100). While immobilized C1q was shown to enhance FcR-and CRmediated phagocytosis by macrophages, it was shown to inhibit monocyte phagocytosis of surfactant protein A (SP-A)-opsonized bacteria (101). This was not observed with alveolar macrophages (101) . Like MBL, SP-A is a member of the collectin family (6) . The mechanism of this inhibition is unclear (101) .
C1q regulates granulocytes, mast cells and fibroblasts
Soluble C1q stimulates mast cell, neutrophil and eosinophil chemotaxis (102) (103) (104) (Figure 2 ). In view that C1q is predominantly found in the plasma, the significance of C1q in chemotaxis is unclear. However, this is clearly significant for newly synthesized C1q in peripheral tissues (47) . If C1q secreted from macrophages and DCs in peripheral tissues translocates to the blood circulation, it is likely to form radial C1q gradients under steady state originating from tissue macrophages and DCs. Immobilized C1q induces respiratory burst in neutrophils causing the production of O 2 - (105) . This involves the activation of Ca 2+ signaling in neutrophils (105) . Unlike macrophages, neutrophils do not exhibit FcRmediated phagocytosis upon stimulation on immobilized C1q (105) . Immobilized C1q also failed to induce the release of primary and secondary granules from neutrophils (105) . C1q, especially when it binds to bacteria Staphylococci, stimulates neutrophil respiratory burst and up-regulates CR3 expression (106) .
In a recent study, it was shown that IL-6 induction from mast cells, by antibody-opsonized bacteria L. monocytogenes, is dependent on the presence of C1q and integrin α2β1 expression on mast cells (107) . Antibody-opsonized L. monocytogenes failed to induce IL-6 from mast cells when either C1q
-/-mouse serum or α2 -/-mast cells were used. It suggests that bacteria-bound C1q engages integrin α2β1 to provide a co-stimulatory signal through α2β1 signaling which synergizes with other receptors, i.e., FcR and CR, to induce IL-6 from mast cells (107) . Mast cells adhere to immobilized C1q through the α2β1 integrin (107) .
C1q can regulate fibroblast migration and apoptosis. It stimulates fibroblast intracellular Ca 2+ rise leading to K + channel activation and fibroblast chemotaxis (114) . An independent study showed that proliferating fibroblasts enter mitotic arrest and apoptosis upon stimulation with C1q or its collagenous region and this is associated with p38 MAPK phosphorylation in fibroblasts (115) . Inhibition of p38 abrogated fibroblast response to C1q. Pre-incubation of fibroblasts with anti-CRT antibody inhibited C1q stimulation of p38 phosphorylation (115) . This raises another regulatory role of tissue C1q in tissue remodeling where it is produced by macrophages and DCs.
C1q in immunity and tolerance
The central conduit of C1q functions is its association with the C1r 2 C1s 2 to form the complement C1 complex. Variations of its function arise from its selective ligand recognition which targets this complex to various patho-physiologically relevant entities. Its ability to elicit lethal attack by producing opsonins, anaphylatoxins and lytic complexes is well understood. When the targets are host entities, this is tightly regulated through multiple inhibitory mechanisms including C1 inhibitor, C4-binding protein (C4BP), factor I, factor H, DAF, MCP, CR1 and CD59 (1) . Even the targets are microbial pathogens, some of these control mechanisms are also in place to limit the scale of complement consumption and consequent tissue damages. For example, factor I and factor H cleave C4b and C3b on microorganisms as well as on host cells to reduce complement activation. However, DAF, MCP, CR1 and CD59 are largely restricted to host cells for the control of complement activation. AC has been increasingly recognized as a target of C1q-mediated complement activation which has distinct or opposite consequences from its activation on microorganisms. AC-loaded APCs appear to be tolerogenic, or immunosuppressive, and this is largely consistently reported for C1q-opsonized AC. A number of mechanisms may contribute the immunosuppressive property of C1q-opsonized AC. Firstly, phagocytosis of C1q-opsonized AC mediated by CD91 is likely to activate ERK or PI3K in APCs (18, 77, 92) . ERK activation favours IL-10 production (93). ACstimulated macrophages indeed produce more IL-10 and less IL-12 (116) . PI3K activation, which can be potentially elicited through gC1qR, is known to inhibit IL-12 production (117).
Secondly, when complement is elicited on AC, this is likely to be limited by various inhibitory mechanisms leading to the deposition of C3 or C4 opsonins without generating significant C5a anaphylatoxin and lytic complexes. Under steady state, macrophages synthesize early but not late complement components such as C5-C9 (40) . It is unclear what other complement components are produced in peripheral tissues by other cells. If C5-C9 is absent or scarce in peripheral tissues, complement activation on AC naturally reduces or ceases after C3 opsonin deposition and this is not expected to cause significant inflammation and tissue damages associated with anaphylatoxins and lytic complexes. Besides membrane destruction, activated late complement components (C5b-C9) also activate DC production of IL-12 and TNF-α and such DCs promote immunity rather than tolerance (118) .
When AC is bound by CRP, the activation of late complement components can be inhibited through two additional mechanisms. CRP can limit the activation of late complement components on AC by binding to factor H which enhances C3b cleavage into iC3b (71) . It also up-regulates surface expression of DAF, MCP and CD59 on host cells although whether this occurs on AC is unclear (72) . CRP is an acute phase protein and is likely to be significant under inflammatory conditions when plasma complement infiltrates peripheral tissues (119) . It is also unclear how C1q-mediated complement activation on polyclonal IgM-opsonized AC is controlled under inflammatory conditions. The report that SAP -/-mice developed autoimmunity, like C1q -/-mice, is consistent with its binding to AC and triggering of C1q-mediated complement activation (14, 91) . The exact mechanism by which SAP control complement activation on AC is unclear. Thirdly, C3 deposition on AC, especially iC3b, can effectively regulate phagocyte activation. Ligation of the iC3b receptor CR3 on macrophages inhibits IL-12 production (35, 36) . Phagocytosis of iC3b-opsonized AC by DCs renders these cells tolerogenic (25) . The ability of C1q to elicit iC3b deposition on AC without inducing inflammation and tissue damages can result in suppression of phagocyte activation or render APCs tolerogenic while promoting AC uptake.
Summary
The structure of C1q, as a major component of the complement system, has been extensively investigated providing an elegant model for the investigation of its functions. While its primary role in the complement system is the formation of C1 complex with the C1r 2 C1s 2 proteases and its ability to bind different ligands directs complement activation on different targets, growing evidence suggests a broader regulatory role for C1q. It remains to be investigated why C1q expression is restricted to monocyte-derived macrophages and dendritic cells. Since these are major antigen-presenting cells, this mode of C1q synthesis may regulate antigen presentation and adaptive immunity. It is also not fully understood how C1q-deficiency is associated with autoimmunity. C1q is synthesized from three distinct types of chains. In the absence of one or two C1q chains, can the remaining chains form a C1q-like molecule? The expression of recombinant C1q may explain some of these questions. In addition, although isolated collagenous and globular domains of C1q have been widely used to locate its binding sites for various ligands or effector molecules, specific C1q binding sites for these molecules also require the expression of recombinant C1q.
